Kevin Outterson

Kevin Outterson was a panelist for the Forum’s discussions on Drug-Resistant Infections.

Professor Kevin Outterson is the director of the Social Innovation on Drug Resistance (SIDR) Program. He teaches health law and corporate law at Boston University, where he is the N. Neal Pike Scholar in Health and Disability Law and co-directs the Health Law Program, currently ranked #3 in the country by US News and World Report. He is the executive director of Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global partnership hosted at BU Law that is focused on supporting developers of promising new antibiotics, diagnostics, and vaccines that tackle the threat of untreatable bacterial infections. He serves as the editor-in-chief of the Journal of Law, Medicine & Ethics; faculty co-advisor to the American Journal of Law & Medicine; past chair of the Section on Law, Medicine & Health Care of the AALS; and a member of the Board of the American Society of Law, Medicine & Ethics. Professor Outterson was recently named to the Advisory Panel for the Longitude Prize, which awards £10 million to address antibiotic resistance. Before teaching, Outterson was a partner at two major US law firms.

His research focuses on the organization and finance of the health sector. Areas of specialization include global pharmaceutical markets, particularly antibiotics and other antimicrobials that can degrade in usefulness over time through resistance. He received a grant from the European Union’s Innovative Medicines Initiative to study business models and incentives for antibiotic development, and he leads an interdisciplinary project on the legal ecology of antimicrobial resistance, funded in part by the Robert Wood Johnson Foundation program on public health law. He is an associate fellow at the Royal Institute of International Affairs at Chatham House, London, where he works on global solutions to antibiotic resistance, and an appointed member of the Antimicrobial Resistance Working Group at the Centers for Disease Control.

Professor Outterson has testified before President Obama’s Advisory Council on Combating Antibiotic Resistance, where he presented the results of a two-year study sponsored by the European Union on designing economic incentives for antibiotic development.

  • Click here for a BU Research interview about Professor Outterson’s work on antibiotic resistance.

Another significant body of work critiques access and equity issues created by global patent and drug regulation laws. Key texts in this debate include the WTO TRIPS Agreement and related trade agreements.

Professor Outterson publishes in both legal journals (Yale Journal of Health Policy, Law & Ethics; Cardozo Law Review; University of Pittsburgh Law Review; Kansas Law Review; American Journal of Law & Medicine) and peer-reviewed medical and health policy journals (New England Journal of Medicine; Health Affairs; Lancet Infectious Diseases; Environmental Philosophy; Medical Journal of Australia; Journal of Generic Medicines; Clinical Infectious Diseases; Journal of Law, Medicine & Ethics). He blogs on health policy issues at The Incidental Economist, one of the leading health economics blogs in the US.

On behalf of The New England Journal of Medicine and other clients, Outterson filed an amicus brief in the US Supreme Court, supporting Vermont’s prescription privacy law. His work was cited by Justice Breyer in Sorrell v. IMS Health. A team led by Professors Outterson and Moncrieff at Boston University filed four amicus briefs supporting the Affordable Care Act, which was heard by the Court in the spring of 2012.

His academic papers can be found on his SSRN page.